At Jazz, our purpose is to innovate to transform the lives of patients and their families. In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies.

At Jazz, we push ourselves and other stakeholders to think holistically about patients’ health to minimize the risk of patient co-morbidities and address significant unmet needs. To learn more about the often-overlooked co-morbidities associated with narcolepsy and the progress Jazz has made to address them, Jazz's Dr. Todd Kirby spoke with sleep specialist Dr. Richard K. Bogan. 

At Jazz Pharmaceuticals, we’re committed to developing life-changing medicines for people affected by serious diseases for which current therapies are lacking. This begins with talking to those living with disease and reflecting their needs in our R&D priorities and throughout all stages of our drug development process as we pursue novel, meaningful medicines that advance patient care.

In recognition of International Lennox-Gastaut Syndrome (LGS) Awareness Day, which takes place every year on November 1, we sat down with Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation, to discuss the importance of raising awareness of LGS – a developmental brain disorder that frequently evolves from early-life-onset epilepsy – and share her family’s personal journey with the disease. 

By helping to bridge the gaps that can sometimes occur between academics and companies when conducting clinical translational research, the SU2C Catalyst program embodies the type of multisectoral partnerships that we at Jazz know are integral to addressing some of the largest hurdles in healthcare.

As part of our commitment to the cancer community, Jazz actively seeks out and listens to patients, physicians, care teams and advocacy groups for insights that could help develop new or better standards of care for rare and difficult-to-treat cancers.